PURPOSE: The diagnostic accuracy of [(18)F]fluorodeoxyglucose (FDG) PET is insufficient to characterise hepatocellular carcinoma (HCC) in liver masses and to diagnose all cases of recurrent HCC. HCC has been reported to take up [(11)C]acetate, but routine use of this tracer is difficult. Choline is another tracer of lipid metabolism, present in large amounts in HCC. In a proof-of-concept study, we evaluated [(18)F]fluorocholine (FCH) uptake by HCC and compared FCH PET/CT with FDG PET/CT. METHODS: Twelve patients with newly diagnosed (n=8) or recurrent HCC (n=4) were prospectively enrolled. HCC was assessed by histology in eight cases and by American Association for the Study of Liver Diseases (AASLD) criteria in four cases. All patients underwent whole-body PET/CT 10 min after injection of 4 MBq/kg FCH. Within 1 week, 9 of the 12 patients also underwent whole-body FDG PET/CT 1 h after injection of 5 MBq/kg FDG. RESULTS: The per-patient analysis showed a detection rate of 12/12 using FCH PET/CT for both newly diagnosed and recurrent HCC. The median signal to noise ratio was 1.5+/-0.38. There was a trend towards a higher FCH SUV(max) in well-differentiated HCC (15.6+/-7.9 vs 11.9+/-0.9, NS). Of the nine patients who underwent FCH and FDG PET/CT, all nine were positive with FCH whereas only five were positive with FDG. CONCLUSION: FCH provides a high detection rate for HCC, making it potentially useful in the initial evaluation of HCC or in the detection of recurrent disease. The favourable result of this proof-of-concept study opens the way to a phase III prospective study.
PURPOSE: The diagnostic accuracy of [(18)F]fluorodeoxyglucose (FDG) PET is insufficient to characterise hepatocellular carcinoma (HCC) in liver masses and to diagnose all cases of recurrent HCC. HCC has been reported to take up [(11)C]acetate, but routine use of this tracer is difficult. Choline is another tracer of lipid metabolism, present in large amounts in HCC. In a proof-of-concept study, we evaluated [(18)F]fluorocholine (FCH) uptake by HCC and compared FCH PET/CT with FDG PET/CT. METHODS: Twelve patients with newly diagnosed (n=8) or recurrent HCC (n=4) were prospectively enrolled. HCC was assessed by histology in eight cases and by American Association for the Study of Liver Diseases (AASLD) criteria in four cases. All patients underwent whole-body PET/CT 10 min after injection of 4 MBq/kg FCH. Within 1 week, 9 of the 12 patients also underwent whole-body FDG PET/CT 1 h after injection of 5 MBq/kg FDG. RESULTS: The per-patient analysis showed a detection rate of 12/12 using FCH PET/CT for both newly diagnosed and recurrent HCC. The median signal to noise ratio was 1.5+/-0.38. There was a trend towards a higher FCH SUV(max) in well-differentiated HCC (15.6+/-7.9 vs 11.9+/-0.9, NS). Of the nine patients who underwent FCH and FDG PET/CT, all nine were positive with FCH whereas only five were positive with FDG. CONCLUSION:FCH provides a high detection rate for HCC, making it potentially useful in the initial evaluation of HCC or in the detection of recurrent disease. The favourable result of this proof-of-concept study opens the way to a phase III prospective study.
Authors: T R DeGrado; R E Coleman; S Wang; S W Baldwin; M D Orr; C N Robertson; T J Polascik; D T Price Journal: Cancer Res Date: 2001-01-01 Impact factor: 12.701
Authors: M A Khan; C S Combs; E M Brunt; V J Lowe; M K Wolverson; H Solomon; B T Collins; A M Di Bisceglie Journal: J Hepatol Date: 2000-05 Impact factor: 25.083
Authors: Daniel T Schmid; Hubert John; Roland Zweifel; Tibor Cservenyak; Gerrit Westera; Gerhard W Goerres; Gustav K von Schulthess; Thomas F Hany Journal: Radiology Date: 2005-05 Impact factor: 11.105
Authors: S Okazumi; K Isono; K Enomoto; T Kikuchi; M Ozaki; H Yamamoto; H Hayashi; T Asano; M Ryu Journal: J Nucl Med Date: 1992-03 Impact factor: 10.057
Authors: John Kurhanewicz; Daniel B Vigneron; Kevin Brindle; Eduard Y Chekmenev; Arnaud Comment; Charles H Cunningham; Ralph J Deberardinis; Gary G Green; Martin O Leach; Sunder S Rajan; Rahim R Rizi; Brian D Ross; Warren S Warren; Craig R Malloy Journal: Neoplasia Date: 2011-02 Impact factor: 5.715
Authors: Eugen Kubala; Kim A Muñoz-Álvarez; Geoffrey Topping; Christian Hundshammer; Benedikt Feuerecker; Pedro A Gómez; Giorgio Pariani; Franz Schilling; Steffen J Glaser; Rolf F Schulte; Marion I Menzel; Markus Schwaiger Journal: J Vis Exp Date: 2016-12-30 Impact factor: 1.355
Authors: Jae Hyun Han; Dong Goo Kim; Gun Hyung Na; Eun Young Kim; Soo Ho Lee; Tae Ho Hong; Young Kyoung You Journal: World J Gastroenterol Date: 2014-12-07 Impact factor: 5.742